Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
Fox RJ, Cree BAC, de Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Singh CM, Altincatal A, Belviso N, Avila RL, Ho PR, Su R, Engle R, Sangurdekar D, de Moor C, Fisher E, Kieseier BC, Rudick RA. Fox RJ, et al. Among authors: rudick ra. Neurology. 2024 May 14;102(9):e209357. doi: 10.1212/WNL.0000000000209357. Epub 2024 Apr 22. Neurology. 2024. PMID: 38648580 Clinical Trial.
Magnetic resonance fingerprinting in multiple sclerosis.
Ontaneda D, Gulani V, Deshmane A, Shah A, Guruprakash DK, Jiang Y, Ma D, Fisher E, Rudick RA, Raza P, Kilbane M, Cohen JA, Sakaie K, Lowe MJ, Griswold MA, Nakamura K. Ontaneda D, et al. Among authors: rudick ra. Mult Scler Relat Disord. 2023 Nov;79:105024. doi: 10.1016/j.msard.2023.105024. Epub 2023 Sep 27. Mult Scler Relat Disord. 2023. PMID: 37783196
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial.
Cutter G, Rudick RA, de Moor C, Singh CM, Fisher E, Koster T, Lublin FD, Wolinsky JS, McFarland H, Jacobson S, Naylor ML. Cutter G, et al. Among authors: rudick ra. Mult Scler J Exp Transl Clin. 2023 Apr 27;9(2):20552173231169463. doi: 10.1177/20552173231169463. eCollection 2023 Apr-Jun. Mult Scler J Exp Transl Clin. 2023. PMID: 37139460 Free PMC article.
Epsilon toxin-producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege.
Ma Y, Sannino D, Linden JR, Haigh S, Zhao B, Grigg JB, Zumbo P, Dündar F, Butler D, Profaci CP, Telesford K, Winokur PN, Rumah KR, Gauthier SA, Fischetti VA, McClane BA, Uzal FA, Zexter L, Mazzucco M, Rudick R, Danko D, Balmuth E, Nealon N, Perumal J, Kaunzner U, Brito IL, Chen Z, Xiang JZ, Betel D, Daneman R, Sonnenberg GF, Mason CE, Vartanian T. Ma Y, et al. Among authors: rudick r. J Clin Invest. 2023 May 1;133(9):e163239. doi: 10.1172/JCI163239. J Clin Invest. 2023. PMID: 36853799 Free PMC article.
Associations of sNfL with clinico-radiological measures in a large MS population.
Sotirchos ES, Fitzgerald KC, Singh CM, Smith MD, Reyes-Mantilla M, Hersh CM, Hyland MH, Canissario R, Simmons SB, Arrambide G, Montalban X, Comabella M, Naismith RT, Qiao M, Krupp LB, Nicholas JA, Akgün K, Ziemssen T, Rudick R, Fisher E, Bermel RA, Mowry EM, Calabresi PA. Sotirchos ES, et al. Among authors: rudick r. Ann Clin Transl Neurol. 2023 Jan;10(1):84-97. doi: 10.1002/acn3.51704. Epub 2022 Nov 25. Ann Clin Transl Neurol. 2023. PMID: 36427295 Free PMC article.
Benefits of early treatment with natalizumab: a real-world study.
Ontaneda D, Mowry EM, Newsome SD, Naismith RT, Nicholas J, Fisher E, de Moor C, Bohn J, Ho PR, Sandrock A, Rudick R, Williams JR. Ontaneda D, et al. Among authors: rudick r. Mult Scler Relat Disord. 2022 Dec;68:104216. doi: 10.1016/j.msard.2022.104216. Epub 2022 Oct 3. Mult Scler Relat Disord. 2022. PMID: 36288658 Free article.
Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics.
Hersh CM, Altincatal A, Belviso N, Kapadia S, de Moor C, Rudick R, Williams JR, Miller C, Koulinska I. Hersh CM, et al. Among authors: rudick r. Mult Scler J Exp Transl Clin. 2022 Jan 7;8(1):20552173211069852. doi: 10.1177/20552173211069852. eCollection 2022 Jan-Mar. Mult Scler J Exp Transl Clin. 2022. PMID: 35024161 Free PMC article.
Measuring treatment response to advance precision medicine for multiple sclerosis.
Calabresi PA, Kappos L, Giovannoni G, Plavina T, Koulinska I, Edwards MR, Kieseier B, de Moor C, Sotirchos ES, Fisher E, Rudick RA, Sandrock A. Calabresi PA, et al. Among authors: rudick ra. Ann Clin Transl Neurol. 2021 Nov;8(11):2166-2173. doi: 10.1002/acn3.51471. Epub 2021 Oct 26. Ann Clin Transl Neurol. 2021. PMID: 34704393 Free PMC article. Clinical Trial.
Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.
Hersh CM, Kieseier B, de Moor C, Miller DM, Campagnolo D, Williams JR, Fitzgerald KC, Xiong K, McGinley MP, Hyland M, Rudick RA, Ziemssen T, Koulinska I. Hersh CM, et al. Among authors: rudick ra. Mult Scler J Exp Transl Clin. 2021 Apr 15;7(2):20552173211004634. doi: 10.1177/20552173211004634. eCollection 2021 Apr-Jun. Mult Scler J Exp Transl Clin. 2021. PMID: 33948221 Free PMC article.
270 results